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Abstract
Background
There is limited information on the costs and benefits of alternative adjunct non-
pharmacological treatments for knee osteoarthritis and little guidance on which should be
prioritised for commissioning within the NHS. This study estimates the costs and benefits of
acupuncture, braces, heat treatment, insoles, interferential therapy, laser/light therapy,
manual therapy, neuromuscular electrical stimulation, pulsed electrical stimulation, pulsed
electromagnetic fields, static magnets and transcutaneous electrical nerve Stimulation
(TENS), based on all relevant data, to facilitate a more complete assessment of value.
Methods
Data from 88 randomised controlled trials including 7,507 patients were obtained from a sys-
tematic review. The studies reported a wide range of outcomes. These were converted into
EQ-5D index values using prediction models, and synthesised using network meta-analysis.
Analyses were conducted including firstly all trials and secondly only trials with low risk of
selection bias. Resource use was estimated from trials, expert opinion and the literature. A
decision analytic model synthesised all evidence to assess interventions over a typical treat-
ment period (constant benefit over eight weeks or linear increase in effect over weeks zero
to eight and dissipation over weeks eight to 16).
Results
When all trials are considered, TENS is cost-effective at thresholds of £20–30,000 per
QALY with an incremental cost-effectiveness ratio of £2,690 per QALY vs. usual care.
When trials with a low risk of selection bias are considered, acupuncture is cost-effective
with an incremental cost-effectiveness ratio of £13,502 per QALY vs. TENS. The results of
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Conclusions
Using the £20,000 per QALY NICE threshold results in TENS being cost-effective if all trials
are considered. If only higher quality trials are considered, acupuncture is cost-effective at
this threshold, and thresholds down to £14,000 per QALY.
Introduction
Patients with knee osteoarthritis have a range of treatment options available including phar-
macological, non-pharmacological and surgical management. During the last decade emphasis
has shifted to non-pharmacological management[1] and it is generally accepted that patients
should be offered education, exercise and if appropriate weight management strategies[2]. The
role of other adjunct non-pharmacological therapies that can be used alongside these core
interventions is less clear.
The only additional non-pharmacological therapies recommended by the European League
Against Rheumatism (EULAR) guidelines are the use of appliances (sticks, insoles, knee brac-
ing and other assistive devices) and appropriate footwear[1, 3]. In the UK, the National Insti-
tute for Health and Care Excellence (NICE) guideline[2] recommends local heat and cold,
manual therapy, transcutaneous electrical nerve stimulation (TENS), braces, joint supports,
insoles and assistive devices. Acupuncture was the only non-pharmacological adjunct treat-
ment explicitly not recommended by NICE though a range of other interventions was
reviewed. The EULAR recommendations were based on randomised controlled trials (RCTs),
observational studies and previous systematic reviews and meta-analyses. NICE recommenda-
tions took in to account similar evidence but also reviewed economic evidence and included
specifically commissioned meta-analyses and economic analyses.
Decision makers ideally require comparable estimates of the costs and effects of all alterna-
tive interventions, based on all relevant evidence, to allow their value to be assessed head-to-
head. However, both EULAR and NICE guidance were based on meta-analyses, individual
RCTs or cost-effectiveness studies which typically focused on the comparison of two interven-
tions. Using such “pairwise” intervention comparisons to understand the comparative costs
and benefits of all available therapies is challenging due to differences in study methods, out-
comes and inconsistencies in results.
In addition, both EULAR and NICE guidance were informed by comparisons of interven-
tions using a wide range of patient reported outcomes. Health care decision makers need to
make investment decisions across clinical areas and therefore require a common outcome
measure. In many jurisdictions, the Quality-Adjusted Life Year (QALY) is used[4]. The QALY
reflects an individual’s remaining life expectancy weighted by some measure of health related
quality of life (HRQoL). In this context HRQoL is typically measured using an instrument
which is relevant across clinical areas and for which data reflecting the general public’s prefer-
ences for different HRQoL outcomes is available, such as the EQ-5D[5] measure preferred by
NICE[6].
The objective of this study is to assess the cost-effectiveness of a range of adjunct non-
pharmacological interventions for use in knee osteoarthritis patients within the UK National
Health Service (NHS) using consistent methods to estimate costs and QALYs. Generating
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comparable estimates that incorporate all relevant evidence for all treatments is challenging.
Each available RCT compares a small subset of the available interventions. Furthermore, the
EQ-5D is rarely reported, and the HRQoL data that is reported varies. We therefore use net-
work meta-analysis (NMA) and statistical mapping techniques to address these challenges.
Methods
Overview
The economic evaluation compares the adjunct non-pharmacological interventions in Table 1
to assess whether any of them represent a cost-effective use of UK NHS resources when used
in a general cohort of patients with knee osteoarthritis (age>55 years). The study is conducted
from the perspective of the UK NHS and Personal Social Services (PSS). Individuals with oste-
oarthritis of the knee are usually managed within primary care and may receive these treat-
ments in this context, or via referral (including self-referral) to a musculoskeletal outpatient
physiotherapy service. Usual care can be defined as any standard care package which may
incorporate regular or intermittent follow-up, self-management strategies, analgesics, educa-
tion and exercise advice[7]. Given the heterogeneity in what may constitute usual care in prac-
tice, the objective of this analysis was to estimate the incremental benefits and costs of the
therapies listed in Table 1 over and above those associated with usual care rather than to quan-
tify the outcomes and costs expected under usual care. The interventions appraised are
expected to impact on pain and functioning but not on disease progression. Our evaluation
therefore focuses on such HRQoL changes as the goal of intervention.
The evaluation comprised two components. Firstly a process of statistical mapping and
NMA was used to provide comparable estimates of the effect of each intervention on HRQoL
measured using the EQ-5D. Statistical mapping techniques[8] were used to translate the vari-
able HRQoL data reported in each RCT to EQ-5D estimates. NMA, an extension of conven-
tional pairwise meta-analysis, was then used to combine evidence from trials comparing
different sets of interventions[9–11]. The second component used a decision model to trans-
late these estimates of EQ-5D to QALYs and to estimate costs. Although knee osteoarthritis is
a chronic condition, the analysis focuses on the benefit of treatment within a typical treatment
period (8 weeks in the UK) as there is limited evidence on the longer-term effects of these
interventions.[12] The impact of longer term benefits is explored in sensitivity analyses and
returned to in the Discussion. Given the eight week time horizon, no discounting was applied.
Table 1. Interventions evaluated.
Acupuncture
Appliances Braces
Insoles
Electrotherapy Interferential therapy
Laser/light therapy
Neuromuscular electrical stimulation (NMES)
Pulsed electrical stimulation
Pulsed electromagnetic fields
Transcutaneous electrical stimulation (TENS)
Manual therapy
Static magnets
Heat treatment
Usual care
doi:10.1371/journal.pone.0172749.t001
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Clinical data
RCTs were identified from a previous systematic review[7]. RCTs were required to have
assessed pain as a primary or secondary outcome in adults with knee osteoarthritis and popu-
lation mean age55 years. The systematic review identified 152 RCTs. For five of the identi-
fied studies individual patient data (IPD) were made available from the Acupuncture Trialists’
Collaboration (ATC) repository[13]. IPD are preferred to the data available in published
reports as they allow analyses to be tailored to the study question and a consistent analytic
approach across studies. Studies were included in the current analysis if reported mean scores
for all dimensions of any HRQoL measure listed below (see section ‘Translation of clinical
data to EQ-5D estimates’) for one or more post-baseline time points. Studies were included if
they reported absolute values, or reported change from baseline alongside baseline data and
therefore allowed calculation of absolute values. This allowed 88 studies and 7,507 patients to
be included as shown in Fig 1. Follow-up assessments and treatment duration varied across
studies. The analysis included data that was reported closest to eight weeks from baseline and
whilst patients were on treatment or within two weeks after planned treatment ended. A full
list of the included studies and data is provided in the Supplementary Material.
Some interventions were included in the systematic review and NMA but not in the cost-
effectiveness analysis. Exercise and weight loss were excluded from the cost-effectiveness anal-
ysis as they are core treatments rather than adjunct therapies[2]. Balneotherapy was excluded
as it is not used in the UK; ice/cooling treatment was excluded as this is a common self-
management strategy with no/minimal cost and no known risk[2] and placebo and sham acu-
puncture were excluded as it was not expected that either would be prescribed. However all of
these interventions were retained in the NMA as they strengthened the network of evidence
and provided indirect data to inform HRQOL comparisons of the interventions of interest.
Usual care and ‘no intervention’ were pooled as trial reporting did not allow these comparators
to be clearly distinguished, and it was expected as all patients included in the trials were diag-
nosed with osteoarthritis they would be receiving some form of care.
The studies were generally poor quality: only nine (10%) were considered at overall low risk
of bias according to the Cochrane risk of bias tool [14]. A previous meta-epidemiologic study
of 16 meta-analyses comparing active to control interventions or placebo in patients with hip
or knee osteoarthritis found effect sizes to be higher in studies with unclear or inadequate allo-
cation concealment compared to those with adequate allocation concealment according to the
Cochrane risk of bias tool [15]. Two different sets of trials were therefore analysed: all 88 trials
and 39 trials with low risk of bias for allocation concealment (referred to as trials at low risk of
selection bias)[15]. An analysis restricted to trials considered at overall low risk of bias accord-
ing to the Cochrane risk of bias tool was not possible due to the absence of a connected net-
work of RCTs.
Translation of clinical data to EQ-5D estimates
The HRQoL instrument(s) collected and reported varied considerably across trials. The EQ-
5D was our preferred endpoint to generate QALY estimates given NICE’s preference for the
measure.[6] We therefore focused on HRQoL instruments for which a mapping algorithm to
EQ-5D was available, identified using a published database[16].
The following hierarchy of HRQoL instruments was used to select data for synthesis (see
reference in brackets for mapping algorithm): EQ-5D preference values; SF-36 dimension
scores[17]; SF-36 mental and physical component summary[18]; SF-12 mental and physical
component summary[19]; Western Ontario and McMaster Universities Arthritis Index total
score;[20] pain visual analogue scale[18]; and pain numerical rating scale[21]. Fig 2
Cost-effectiveness of knee osteoarthritis therapies
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summarises the data available for each pairwise comparison. The mapping approaches are
detailed in the Supplementary Material.
Network Meta-Analysis (NMA) of EQ-5D estimates
A NMA of the continuous EQ-5D outcome was conducted on both data sets (all trials and tri-
als at low risk of selection bias). The model extended a previously developed IPD model to
include aggregate published data.[22] The model assumed treatment effects were transitive on
the absolute EQ-5D scale, that is, the treatment effect for treatment B compared to treatment
A (dAB) can be estimated as dAC—dBC[23]. As differences in study designs, populations, and
the implementation of interventions seemed likely to generate heterogeneity in the underlying
true treatment effects, random effects models were applied. The NMA was conducted using
Bayesian methods due to the flexibility these methods afford; full statistical methods are
reported in the Supplementary Material. The NMA included all interventions in the systematic
Fig 1. Patients randomised to trials included in the network, by comparator and study quality. NMES = neuromuscular electrical stimulation;
TENS = transcutaneous electrical nerve stimulation.
doi:10.1371/journal.pone.0172749.g001
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review with the exception of weight loss, as including trials restricted to overweight patients
was expected to increase heterogeneity within the network.
Cost data
Intervention costs comprised equipment costs and staff time (see Table 2 and references
[24–30]). The costing reflects only the incremental costs associated with interventions. Based
on clinical opinion, background usual care costs were expected to apply equally across trial
arms, and were therefore omitted. Staff time for delivering interventions was estimated using
the weighted average weekly therapist contact time across the included RCTs. This reflects the
overall therapist time across multiple sessions, if applicable. Expert opinion from a GP and
Fig 2. Best available quality of life data by intervention comparison. Each row denotes a pairwise comparison of interventions for which randomised
controlled trial data was available. The number of symbols in each row reflects the number of trials making that comparison, shape size is proportional to
the size of each study and the type of shape indicates the health related quality of life instrument used. Studies informing multiple comparisons (due to the
presence of three or more trial arms) appear for each comparison. MCS = mental component summary score; NMES = neuromuscular electrical
stimulation; NRS = numerical rating scale; PCS = physical component summary scores; TENS = transcutaneous electrical nerve stimulation; VAS = visual
analogue scale; WOMAC = Western Ontario and McMaster Universities Arthritis Index.
doi:10.1371/journal.pone.0172749.g002
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physiotherapist working with patients with osteoarthritis of the knee indicated that weekly
appointments would not be required for braces, heat treatment sleeves, insoles, static magnets
or TENS and that instead these would require one 40 minute appointment for prescription
and in the case of insoles and braces one further 30 minute follow-up. Because of the UK NHS
perspective, costs of delivering acupuncture were based on physiotherapists’ time. For durable
equipment (insoles, braces, static magnets) benefits and costs were assumed to be spread
across their useable lifetimes. We assumed TENS machines would be used at home for eight
weeks and then returned for use by other patients. Costs of consumables, costs per use for
machines available at physiotherapy units and any intervention-specific training costs were
not included as they were expected to be small.
Interventions which improve symptoms may have indirect effects on health care utilisation.
None of the included RCTs reported relevant healthcare utilisation data for the UK. Therefore,
Table 2. Resource use and unit costs (cost year 2012–13).
Intervention Weekly physiotherapist duration (minutes)a Additional prescription
time (minutes)b
Equipment included in costing,
assumed lifespan cData from all trials Data from trials with low
risk of selection bias
Weighted
average
Min Max Weighted
average
Min Max
Acupuncture 37 18 80 40 20 50 0 None
Braces 0 0 0 0 0 0 70 Brace 0.5 years
Heat treatment–
diathermy (73%)d
84 60 143 60 60 60 0 None
Heat treatment–sleeve
(27%)d
0 0 0 0 0 0 40 Sleeve 0.5 years
Insoles 0 0 0 0 0 0 70 Insole 1 year
Interferential therapy 159 40 245 245 245 245 0 None
Laser/light therapy 105 25 210 60 60 60 0 None
Manual therapy 63 30 90 57 30 90 0 None
NMES 100 100 100 NAe NAe NAe 0 None
Pulsed electrical
stimulation
82 57 114 85 57 114 0 None
Pulsed electromagnetic
fields
303 80 600 120 120 120 0 None
Static magnets 0 0 0 0 0 0 40 Magnet 2 years +strapf
TENS 0 0 0 0 0 0 40 TENS machine 1 year
Source: Pooled randomised controlled trial data (see text for full
source)
Clinical opinion Clinical opinion
NA = not available (treatment does not provide data to inform network); NMES = neuromuscular electrical stimulation; TENS = transcutaneous electrical
nerve stimulation.
aUnit costs: £36 (hospital physiotherapist, per hour).
bPrescription and follow-up were assumed to be undertaken by a physiotherapist, with the exception of insole prescription and fitting which was assumed to
be carried out by a podiatrist (unit cost £30 for community podiatrist, per hour).
cUnit costs were £88 (Bauerfeind GenuTrain Knee Support brace); £11 (Titanium adjustable knee-heating strap); £50 (Ready-made lateral wedge foot
insole); £50 (Bioflow magnet and separate strap); £35 (TENS digital pain relief unit).
dHeat treatment included trials of diathermy and one trial of a heat retaining sleeve. Their costs were therefore weighted according to the proportion of
patients in the trials.
eNo trials of NMES included in this analysis;
f50% of patients assumed to require a replacement strap during two years of use. Note: Resource use from the Topical or Oral IBuprofen for chronic knee
pain in older people trial was costed as follows: £45 (GP, per visit), £135 (secondary care specialist, per visit).
doi:10.1371/journal.pone.0172749.t002
Cost-effectiveness of knee osteoarthritis therapies
PLOS ONE | DOI:10.1371/journal.pone.0172749 March 7, 2017 7 / 18
data from the Topical or Oral IBuprofen for chronic knee pain in older people (TOIB) trial
[30] were used to estimate the extent to which changes in the EQ-5D yield changes in resource
utilisation. We assumed that information on the relationship between EQ-5D and resource
utilisation from this pharmacological trial was generalizable to the current evaluation of non-
pharmacological therapies. A simple ordinary least squares regression estimated that a 0.10
improvement in the EQ-5D between months three and 12 resulted in a 0.09 (95% CI: -0.02,
0.19) reduction in the number of primary care visits from months zero to three to months
three to 12 and a 0.05 (95% CI: -0.06, 0.16) increase in specialist visits from months zero to
three to months three to 12. This analysis allows for an assessment of whether changes in qual-
ity of life between months three and 12 are associated with changes in resource use between
months zero to three to months three to 12. The results may reflect a lack of effect as the confi-
dence intervals were wide and included zero. We assumed that this relationship between EQ-
5D and resource use could be applied to the model time horizon of eight weeks. For example,
an intervention that improved quality of life by 0.10 compared to usual care would result in a
0.09 reduction in primary care visits and a 0.05 increase in specialist visits over the eight week
period (as any changes in usual care (baseline) EQ-5D cancel out).
Cost-effectiveness analysis
Decision analytic model. The decision analytic model translated EQ-5D estimates to
QALY estimates using the area under the curve method[4]. EQ-5D estimates were assumed to
apply for the eight-week time horizon in order to calculate the area under the curve. This
approach captures different profiles of therapeutic effect. For example, some interventions
(e.g. TENS) may provide rapid relief but confer no residual effect beyond treatment, whereas
others (e.g. acupuncture) may require time to deliver full therapeutic effect but effects may dis-
sipate more gradually following cessation. In the latter case if there is a linear increase in effect
between baseline and week eight followed by a linear decrease between weeks eight and 16 this
will result in the same area under the EQ-5D curve (i.e. QALY estimate) as assuming an
instantaneous and constant benefit which is lost at week eight.
Incremental cost-effectiveness results are presented to allow simultaneous comparison of
all treatments.[4] In each analysis, the most effective intervention with an incremental cost-
effectiveness ratio (ICER) that is less than the cost-effectiveness threshold is the cost-effective
choice. The cost-effectiveness threshold represents the maximum the NHS should be willing
to spend to generate additional QALYs, in the UK values of £20,000–30,000/QALY[6] are typi-
cally used.
Sensitivity analyses. Probabilistic sensitivity analysis was conducted to calculate the prob-
ability that each intervention is cost-effective and to estimate the value of resolving all uncer-
tainty (the value of perfect information). The posterior distribution from the NMA was used
to reflect uncertainty in treatment impacts on EQ-5D, and the uncertainty in the relationship
between EQ-5D and primary care/outpatient resource use was represented using a normal
distribution.
Scenario analyses explored using the shortest/longest weekly therapist time across trials to
determine costs (for braces, insoles, static magnets and TENS, where cost was driven by equip-
ment as well as staff costs, total costs were varied by +/-50%); use of upper and lower 95% cred-
ible intervals for effectiveness; and use of weekly time spent with a therapist that is more
typical of clinical practice within the NHS (20 minutes, or 30 minutes for acupuncture and
manual therapy). The latter analysis is combined with a series of assumptions about how the
weekly time spent with a therapist may affect therapeutic benefit: (i) outcomes increase linearly
with time spent with a therapist; (ii) outcomes increase linearly to a maximum at one hour;
Cost-effectiveness of knee osteoarthritis therapies
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(iii) 75% of outcomes are achieved within 30 minutes and the remaining 25% with the exten-
sion to one hour; and (iv) full benefit is achieved within 20–30 minutes.
Two analyses explored the sensitivity of the model results to the possibility that interven-
tions offer longer-term HRQoL gains. Firstly, a threshold analysis was conducted to identify
the extension to the duration of benefit required to alter the cost-effective intervention when
the benefit of all interventions was extended simultaneously. Secondly, an analysis was con-
ducted to see the impact of extending the benefit of each intervention individually up to a max-
imum of 50% additional benefit, this reflected feedback from clinical experts that impacts on
HRQoL are commonly short-lived and that a linear decline over eight weeks (i.e. 50% addi-
tional benefit) may represent a typical maximum on the possible long-term effects of
interventions.
Results
Effect of interventions on EQ-5D
Fig 3 presents the results of the NMA. The level of uncertainty regarding the effect of some
comparators was very high, particularly for NMES and static magnets. The 95% credible inter-
vals cross zero with the exception of: muscle strengthening exercise and acupuncture (in both
analyses); interferential therapy, pulsed electrical stimulation and TENS (in the all-trials analy-
sis only); and sham acupuncture (in the low risk of selection bias analysis only). The effect of
TENS is smaller and the effect of Tai Chi, sham acupuncture and manual therapy larger when
the analysis is restricted to trials with low risk of selection bias.
Global tests of model fit suggested an adequate fit to the data. However, the model was
unable to fit well to four data points in the all-trials analysis. Two of the data points related to
the trials including interferential therapy as a comparator, these trials all suggest that
Fig 3. Results of network meta-analyses of EQ-5D. Results presented as values corresponding to 2.5%, 50% and 97.5% of the posterior distribution.
NMES = neuromuscular electrical stimulation; TENS = transcutaneous electrical nerve stimulation.
doi:10.1371/journal.pone.0172749.g003
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interferential therapy is beneficial but provide inconsistent information regarding effect size
[31–33]. The two other data points were from a study comparing aerobic exercise to usual care
which has previously been identified as an outlier[12].
Cost-effectiveness of alternative interventions
Results of the cost-effectiveness analysis are presented as Table 3 and Fig 4 for all trials and
Fig 5 for trials with low risk of selection bias. For some options ICERs are not presented
because the intervention is either dominated (generates fewer QALYs and higher costs than
another intervention) or because the intervention is extendedly dominated (generates fewer
QALYs and has a higher ICER than another intervention). Multiple ICERs show the value of
moving to successively more effective interventions. In the analysis of all trials there are two
ICERs. The first ICER is the estimated cost per QALY of moving from usual care to TENS. At
£2,690 per QALY, this ICER is below the threshold of £20,000–30,000 per QALY and would
therefore be considered to represent value for money. The cost per QALY of moving from
TENS to interferential therapy is £33,866 per QALY. This ICER exceeds the threshold range
considered to represent value for money. In the all trials analysis TENS is therefore cost-effec-
tive. In the analysis of trials with low risk of selection bias, the move from usual care to TENS
generates value with an ICER of £6,142 per QALY, and the move from TENS to acupuncture
generates further value with an ICER of £13,502 per QALY. Acupuncture is therefore cost-
effective in this analysis of trials with a low risk of selection bias.
There is a 49% probability that TENS is cost-effective in the all trials analysis (at a cost-
effectiveness threshold of £20,000/QALY) and a 47% probability that acupuncture is cost-
effective in the analysis of trials with low risk of selection bias. The net health benefit of resolv-
ing all uncertainty is 60% greater than the health achieved by making decisions based on
Table 3. Cost effectiveness results.
Intervention All trials Trials at low risk of selection bias
Incremental costs (vs.
usual care)
Incremental QALYs
(vs. usual care)
ICER
(£/QALY)
Incremental costs (vs.
usual care)
Incremental QALYs
(vs. usual care)
ICER
(£/QALY)
Static magnets £5 0.001 ED £5 0.000 Dom
Insoles £13 0.001 ED £13 0.002 ED
TENS £31 0.011 £2,690 £30 0.005 £6,142
Braces £40 0.001 Dom NA NA NA
Acupuncture £179 0.014 ED £192 0.017 £13,502
Heat treatment £297 0.005 Dom £214 0.003 Dom
Manual therapy £304 0.008 Dom £276 0.013 Dom
Pulsed electrical
stimulation
£396 0.011 Dom £410 0.010 Dom
NMES £481 0.005 Dom NA NA NA
Laser light therapy £503 0.007 Dom £288 0.003 Dom
Interferential therapy £770 0.033 £33,866 £1,179 0.016 Dom
Pulsed
electromagnetic fields
£1,453 0.007 Dom £577 0.008 Dom
Dom: Dominated (generates fewer QALYs and equal/higher costs than another intervention); ED = Extendedly dominated (generates fewer QALYs and has
a higher incremental cost-effectiveness ratio than another intervention); NA = not available as no trials of this therapy were available in the analysis.
a Each ICER is calculated as the incremental cost per QALY of the intervention compared to the next less effective intervention which is not dominated or
extendedly dominated. The cost-effective intervention is the most effective intervention which still represents value for money, in the UK ICERs less than
£20–30,000 per QALY are generally considered to represent value for money. The ICER associated with the cost-effective intervention is in bold.
doi:10.1371/journal.pone.0172749.t003
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Fig 4. Cost-effectiveness plane including cost-effectiveness frontier: All trials. Each point denotes a comparator and the line denotes the cost-
effectiveness frontier. This links all non-dominated comparators and therefore shows the set of comparators that could be cost-effective depending upon
the cost-effectiveness threshold. The slope of the line connecting a comparator on the cost-effectiveness frontier to a lower cost comparator is equal to the
incremental cost-effectiveness ratio (ICER). NMES = neuromuscular electrical stimulation; TENS = transcutaneous electrical nerve stimulation.
doi:10.1371/journal.pone.0172749.g004
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Fig 5. Cost-effectiveness plane including cost-effectiveness frontier: Trials at low risk of selection bias. Each point denotes a comparator and the
line denotes the cost-effectiveness frontier. This links all non-dominated comparators and therefore shows the set of comparators that could be cost-
effective depending upon the cost-effectiveness threshold. The slope of the line connecting a comparator on the cost-effectiveness frontier to a lower cost
comparator is equal to the incremental cost-effectiveness ratio (ICER). TENS = transcutaneous electrical nerve stimulation.
doi:10.1371/journal.pone.0172749.g005
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current information for the analysis of all trials; and 50% higher for the analysis of trials at low
risk of selection bias.
The majority of scenario analyses did not alter the cost-effective interventions. Table 4
shows the subset of analyses in which the decision was altered. The results of the analysis were
sensitive to varying weekly time spent with a therapist, effects of interventions on HRQoL, and
to how HRQoL evolves over time.
Discussion
This is the first analysis to provide comparable estimates of costs and QALYs for the range of
adjunct non-pharmacological treatments for knee osteoarthritis, based on all relevant RCT
data.
There is a difference between analyses with respect to whether TENS or acupuncture is the
cost-effective treatment. The all-trials analysis indicates TENS is cost-effective whereas the
Table 4. Results of sensitivity analyses which altered cost-effective intervention.
Dataset Scenario The intervention that is cost-effective
for each scenario at £20,000/QALY
All trials Base case TENS
Shortest weekly therapist time used for
acupuncture costing
Acupuncture
Shortest weekly therapist time used for
interferential therapy costing
Interferential therapy
Shortened weekly therapist time—75% of
benefit in first 30 mins, remainder by 1
hour
Interferential therapy
Shortened weekly therapist time—all
benefit achieved within 20–30 minutes
Interferential therapy
Increase in duration of benefit of all
interventions by 6 weeks
Interferential therapy
Increase in duration of benefit of
acupuncture by 31%
Acupuncture
Increase in duration of benefit of
interferential therapy by 45%
Interferential therapy
Lower 95% CrI from NMA for TENS Acupuncture
Upper 95% CrI from NMA for Acupuncture Acupuncture
Upper 95% CrI from NMA for Braces Braces
Upper 95% CrI from NMA for NMES NMES
Upper 95% CrI from NMA for Static
magnets
Static magnets
Trials at low risk of
selection bias
Base case Acupuncture
Shortened weekly therapist time—all
benefit achieved within 20–30 minutes
Interferential therapy
Lower 95% CrI from NMA for Acupuncture TENS
Upper 95% CrI from NMA for Insoles Insoles
Upper 95% CrI from NMA for Manual
therapy
Manual therapy
Upper 95% CrI from NMA for Static
magnets
Static magnets
Upper 95% CrI from NMA for TENS TENS
NMA = network meta-analysis; NMES = neuromuscular electrical stimulation; TENS = transcutaneous
electrical nerve stimulation; CrI = credible interval.
doi:10.1371/journal.pone.0172749.t004
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analysis restricted to trials at low risk of selection bias indicates that acupuncture is cost-
effective. This difference is driven by a reduction in the TENS treatment effect in the latter
analysis. This suggests that the effect of TENS may be exaggerated in some trials included in
the all trials analysis due to biases associated with poor trial conduct.
There is considerable uncertainty around the effects of interventions—though less so for
acupuncture and muscle-strengthening exercise (as shown in Fig 3) where a relatively large
number of patients informed both the analysis of all trials and the analysis restricted to trials at
low risk of selection bias (as shown in Fig 1). There is also considerable uncertainty in the
probability that each intervention is cost-effective. This reflects uncertainty in effect sizes for
most of the interventions and the large number of interventions. However, decisions regarding
adoption of interventions should not be based on the probability that an intervention is cost-
effective, and instead should reflect the costs and benefits of alternative policy options available
to decision makers[34]. Decision makers can decide to adopt an intervention without further
research, adopt the intervention alongside research or delay adoption until further research is
available[35]. Delaying adoption may be preferable if immediate adoption would impede valu-
able research (for example adoption may remove physicians’ or patients’ incentives to partici-
pate in research). However, delaying adoption also has a cost as the benefits of adopting TENS
or acupuncture during the research period are foregone. In the current analysis decisions
made with perfect information would generate 50%-60% more health than decisions made
with current information. Given that research will take a number of years to report, only par-
tially resolve uncertainty, and incur research costs, it is unlikely that delaying adoption until
further research is available would be beneficial. A further benefit of delayed adoption is that it
avoids upfront investment costs which may turn out to have been unwise if research results in
a reversal of the decision. We do not anticipate upfront costs of sufficient magnitude to make
delaying adoption the preferred policy. Adoption, with or without further research is therefore
the preferred policy.
The recent NICE osteoarthritis guidelines included recommendations regarding the use of
various non-pharmacological adjunct interventions, though they only reviewed economic evi-
dence relating to acupuncture [2]. The NICE Guideline Development Group concluded that
although acupuncture was likely to be cost-effective, it should not be recommended given a
lack of clear clinical benefit over and above sham acupuncture. Our analysis assumes that
sham acupuncture would not be prescribed and that acupuncture should therefore be com-
pared to other viable adjunct interventions (including no adjunct therapy i.e. usual care). Our
analysis also includes all alternative interventions and by doing so finds that some interven-
tions recommended by NICE—namely insoles, braces and manual therapy—are unlikely to be
cost-effective and should not be prioritised for commissioning.
The conclusions of the current work are based on a cost-effectiveness threshold of £20–
30,000 per QALY as this has been historically used by NICE. A cost-effectiveness threshold is
used to assess whether the health benefits offered by an intervention are greater than the health
likely to be lost because the additional resources required are not available to fund other effec-
tive treatments. Research conducted during the course of this study suggests that cost-
effectiveness thresholds of £20–30,000 per QALY may be too high as it estimated that £13,000
of NHS resources adds one QALY to NHS patients [36]. In this study, using this lower estimate
of the cost-effectiveness threshold would result in TENS being the cost-effective choice in both
analyses.
This study has a number of limitations. The underlying quality of the RCTs was generally
poor. This was addressed in this study by performing an analysis of trials at low risk of selec-
tion bias, as this aspect of study quality has been previously found to be a strong marker for
effect bias in osteoarthritis.[15] Nonetheless, this represents only one source of bias, and within
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the studies at low risk of selection bias a number had a high overall risk of bias due to imbal-
ances in baseline characteristics (often caused by small study sizes), a lack of adequate blinding
and a failure to report intention-to-treat results.[7] Unfortunately restricting the analysis to
only those trials at low risk of bias across domains was not feasible due to the low number of
studies that remained. An alternative approach to addressing study bias is to attempt to adjust
for it [37]. In the current context an adjustment approach could be applied to address residual
biases in the studies at low risk of selection bias, or to synthesise all trials whilst adjusting for
biases. However, this type of analysis requires a clear understanding of where biases may be
observed. In comparisons with usual care it may be reasonable to assume the biases act in
favour of active therapy; however in active treatment comparisons it is difficult to predict the
direction of possible biases. In this context the use of elicitation techniques to quantify study-
specific biases may be the most fruitful approach though would be highly resource intensive
given the number of studies.[37]
The analysis focused on the short-term benefits of treatment as there were insufficient data
to provide robust estimates of how HRQoL evolves over time. In an earlier report of the sys-
tematic review underpinning this work, the study authors found that only 23% of those studies
reporting data suitable for synthesis reported data between eight and 16 weeks from the end of
treatment. The available evidence did not form a connected network suitable for analysis, and
much of the evidence was from exercise-related trials and was therefore not directly relevant to
the decision problem considered here. Recent evidence from an analysis of trials in a wider set
of chronic pain conditions (including musculoskeletal pain and headache/migraine as well as
osteoarthritis of the knee) estimated that 90% of the benefit of acupuncture over usual care is
retained at 12 months after the end of a course of treatment.[38] It is plausible that the other
interventions appraised in this study could also continue to directly provide symptomatic ben-
efits beyond the treatment period or, by improving symptoms, could allow individuals to bet-
ter engage with self-management strategies to improve muscle strength and functioning. We
conducted sensitivity analyses examining the impact of extending the duration of all interven-
tion jointly and in turn. This analysis showed that the cost-effective adjunct intervention was
sensitive to extending the duration of all therapies, and the duration of acupuncture and inter-
ferential therapy individually in the analysis of all trials. Though this shows that duration of
therapeutic effect is an important determinant of cost-effectiveness, to establish the implica-
tions of this for decision making, an improved understanding of the long-term effects of all
interventions is required. Further research is required to explore the long-term benefits of the
appraised interventions.
The RCT dataset was heterogeneous. The time point of data collection ranged from one day
to one year, although an analysis restricting the set of trials to those reporting within three-13
weeks did not alter the study results (for further details see MacPherson et al.[39]). There were
variations in the protocol for care, as well as the intensity with which interventions were pro-
vided which may influence outcomes[40], and warrants further exploration. The RCT dataset
included studies conducted in a wide range of countries. Differences in the management of
chronic pain may therefore have contributed to heterogeneity. The variety in HRQoL mea-
sures used in the RCTs necessitated a mapping approach to convert these outcomes to EQ-5D.
Mapping is always a second-best approach compared to directly collecting data on preference
based measures such as the EQ-5D [8]. None of the RCTs provided resource use data that
could be used within the evaluation. We therefore assumed that information on the relation-
ship between EQ-5D and resource utilisation from a pharmacological trial (the TOIB trial)
was generalizable to the current evaluation of non-pharmacological therapies, this assumption
increases uncertainty around the differences across interventions in costs.
Cost-effectiveness of knee osteoarthritis therapies
PLOS ONE | DOI:10.1371/journal.pone.0172749 March 7, 2017 15 / 18
Conclusions
Using the £20–30,000 per QALY NICE threshold (and any threshold up to about £34,000 per
QALY) results in TENS being cost-effective if all trials are considered. If only higher quality
trials are considered, acupuncture is cost-effective at the NICE threshold, at any higher thresh-
olds, and at thresholds down to about £14,000 per QALY.
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